Litigation Details for Cephalon Inc. v. Sandoz Inc. (D. Del. 2014)

« Back to Dashboard

Cephalon Inc. v. Sandoz Inc. (D. Del. 2014)

Docket		Date Filed	2014-09-25
Court	District Court, D. Delaware	Date Terminated	2015-07-10
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,791,270
Link to Docket	External link to docket

Details for Cephalon Inc. v. Sandoz Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-25				External link to document

Cephalon Inc. v. Sandoz Inc. | 1:14-cv-01239 Litigation Summary and Patent Analysis

Last updated: September 26, 2026

Cephalon Inc. v. Sandoz Inc., No. 1:14-cv-01239, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning generic armodafinil, marketed by Cephalon as Nuvigil. The case followed Sandoz’s abbreviated new drug application and patent certifications challenging Cephalon’s Nuvigil patent estate. The dispute ended without a reported merits decision establishing invalidity or noninfringement. Its commercial significance was the timing of generic armodafinil entry after Nuvigil’s regulatory exclusivity had expired and while later-issued formulation and method-of-use patents remained in force.

What drug was at issue in Cephalon v. Sandoz?

The case concerned Nuvigil, the branded version of armodafinil.

Item	Detail
Brand	Nuvigil
Active ingredient	Armodafinil
Sponsor at filing	Cephalon Inc.
Later owner	Teva Pharmaceutical Industries Ltd.
Therapeutic class	Wakefulness-promoting agent
FDA approval	2007
Principal indications	Narcolepsy, obstructive sleep apnea-related excessive sleepiness, and shift-work sleep disorder
Litigation pathway	Hatch-Waxman ANDA litigation
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-01239

Cephalon developed armodafinil as the R-enantiomer of modafinil. Modafinil was marketed as Provigil, while armodafinil was marketed as Nuvigil. The distinction allowed Cephalon to pursue a separate product and a later patent and exclusivity position, even though the products shared pharmacological similarities.

Nuvigil’s original FDA exclusivity period expired before the case was filed. The remaining commercial protection depended primarily on listed patents, including later patents directed to armodafinil formulations and therapeutic use.

What patents protected Nuvigil in the Sandoz litigation?

The litigation involved Cephalon’s later Nuvigil patent estate, including patents directed to armodafinil pharmaceutical compositions and methods of treatment. Public patent records associate the Nuvigil estate with several patents issued after the product’s initial approval.

Principal Nuvigil patent families

Patent	General subject matter	Approximate expiration position
U.S. Patent No. 8,268,349	Armodafinil treatment methods and related pharmaceutical use	2027, subject to patent-term adjustments and listing details
U.S. Patent No. 8,338,457	Armodafinil pharmaceutical use and treatment methods	2027, subject to patent-term adjustments
U.S. Patent No. 8,629,111	Armodafinil pharmaceutical compositions and formulations	2027, subject to patent-term adjustments
U.S. Patent No. 8,871,779	Later-issued Nuvigil-related treatment or composition claims	2027 or later, depending on the specific patent-term calculation

The exact patent claims asserted against Sandoz must be distinguished from the broader set of patents associated with Nuvigil in the Orange Book and related patent records. In Hatch-Waxman litigation, a plaintiff may assert only selected listed patents even when several patents are listed for the same product.

The commercial value of these patents was uneven. Method-of-use claims can be difficult to enforce against a generic product when the ANDA label omits the patented indication or when the plaintiff cannot establish induced infringement. Formulation claims are generally more valuable against an ANDA product if they read directly on the proposed tablet composition.

When did Cephalon file the case against Sandoz?

Cephalon filed the action in 2014 after receiving notice of Sandoz’s ANDA patent certifications. The civil action number is 1:14-cv-01239. The case was assigned to the U.S. District Court for the District of Delaware, a principal venue for pharmaceutical patent litigation.

The filing triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), assuming the statutory requirements were satisfied. That stay generally prevents FDA approval of the ANDA for up to 30 months from the date the brand company receives the Paragraph IV notice, unless the court enters an earlier judgment or the case is otherwise resolved.

Litigation timeline

Date or period	Event
2007	FDA approved Nuvigil
2012 or earlier	Nuvigil’s initial five-year new chemical entity exclusivity period ended, subject to applicable regulatory adjustments
2014	Cephalon filed the Sandoz patent action in Delaware
2014-2015	Pleadings, ANDA-related patent claims, and case management proceedings proceeded
2015 or thereafter	The action ended without a reported trial judgment resolving the validity and infringement disputes
Later period	Generic armodafinil products entered the U.S. market, reducing Nuvigil’s exclusivity and revenue base

The absence of a published merits opinion is material. It means the case did not produce a binding district-court determination that the asserted patents were valid, infringed, or enforceable against Sandoz.

Did Sandoz file a Paragraph IV challenge?

The case was an ANDA patent dispute and therefore involved patent certifications directed to Cephalon’s listed Nuvigil patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

A Paragraph IV filing creates a cause of action for the brand company under the Hatch-Waxman statute. It also can provide the first ANDA filer with 180-day generic drug exclusivity under Section 505(j), although that benefit depends on the timing and status of other first-filer events.

The litigation record does not establish a reported judicial ruling that Sandoz prevailed on a particular Paragraph IV position. The practical result was resolution of the dispute without a published invalidity or noninfringement holding.

What was the litigation status and outcome?

The case did not generate a reported trial verdict or final merits opinion addressing the central patent issues. The docket outcome is best characterized as termination without a publicly reported adjudication of patent validity, infringement, or enforceability.

That outcome limits the precedential value of the case. It does not establish that Cephalon’s Nuvigil patents were weak, nor does it confirm that Sandoz’s proposed product infringed. It indicates that the parties resolved or otherwise terminated the case before a final reported merits decision.

Did Cephalon and Sandoz settle?

The case’s termination is consistent with a negotiated resolution, but the public litigation record does not provide a reported judicial opinion detailing settlement terms such as:

• Authorized generic provisions
• Sandoz’s launch date
• Royalty obligations
• Supply arrangements
• License scope
• Restrictions on marketing or manufacturing
• Treatment of later-issued patents

A settlement should not be treated as a judicial validation of the asserted patents. Nor does the absence of a merits decision indicate that Sandoz would have prevailed.

What was the Orange Book status of Nuvigil?

Nuvigil was listed in the FDA Orange Book with patent information covering armodafinil products. Orange Book listings can include patents directed to active ingredients, drug products, formulations, and methods of use, depending on FDA listing rules and the sponsor’s submissions.

The principal Orange Book relevance was the distinction between:

1. The expiration of FDA regulatory exclusivity; and
2. The later expiration dates of listed patents.

Nuvigil’s regulatory exclusivity did not itself prevent generic development indefinitely. Once the applicable exclusivity expired, an ANDA applicant could seek approval, subject to patent certification and any resulting litigation stay.

Regulatory protection versus patent protection

Protection	Commercial effect
New chemical entity exclusivity	Delayed submission of certain ANDAs during the exclusivity period
Paragraph IV litigation	Could delay approval through the statutory 30-month stay
Listed formulation patents	Could block or complicate approval if the generic product practiced the claims
Method-of-use patents	Could limit labeled indications or create induced-infringement risk
Pediatric exclusivity, if applicable	Could extend the effective regulatory protection period by six months

The relevant patent expiration date for generic entry was therefore not the Nuvigil approval date or the end of NCE exclusivity. It was the enforceable expiration date of the patents that covered the ANDA product and the approved indications.

How strong was Cephalon’s Nuvigil patent estate?

Cephalon’s patent estate had moderate commercial strength but did not create indefinite protection.

Strengths

The estate had several characteristics favorable to the brand company:

• Multiple patents issued after Nuvigil approval.
• Coverage extending well beyond the product’s original regulatory exclusivity.
• Potential formulation claims that could read directly on generic tablets.
• Method-of-use claims covering the commercial treatment indications.
• A Delaware venue with extensive experience in ANDA litigation.
• The ability to obtain a statutory approval stay after a Paragraph IV filing.

Weaknesses

The estate also had structural limitations:

• Armodafinil was a known enantiomer-related product, creating potential obviousness and written-description issues.
• Method-of-use claims can be vulnerable to label-sparing strategies.
• Formulation claims depend heavily on the precise composition and manufacturing process used in the ANDA product.
• Patent expiration around 2027 did not necessarily translate into market exclusivity until that date.
• A settlement could grant an earlier launch date than the nominal patent expiration date.

The absence of a merits judgment leaves no court-tested answer on whether the asserted claims survived validity challenges or covered Sandoz’s product.

What generic entry risks existed for Nuvigil?

Generic entry risk was high once Nuvigil’s regulatory exclusivity expired and multiple ANDA applicants began challenging the listed patents.

The main entry scenarios were:

Scenario	Effect on Cephalon or Teva
Patent victory	Delayed Sandoz approval until patent expiration or a court-authorized entry date
Paragraph IV settlement	Entry on a negotiated date, potentially before patent expiration
Noninfringement finding	Immediate or accelerated generic approval, subject to FDA status
Invalidity finding	Broad loss of patent-based protection
At-risk launch	Generic entry before final appellate resolution, exposing the brand to damages and market erosion
Authorized generic launch	Partial control of price erosion but lower branded share

Generic armodafinil does not require biosimilar approval. It is a small-molecule product reviewed through the ANDA pathway. The relevant competitive issue was therefore generic substitution, not biosimilar interchangeability.

Which companies challenged Nuvigil exclusivity?

Sandoz was one of the ANDA applicants involved in the Nuvigil patent challenge reflected by Civil Action No. 1:14-cv-01239. Other generic manufacturers also pursued armodafinil approval or entered the market over time.

Teva’s position was distinct because it acquired Cephalon and therefore controlled the branded Nuvigil business and the related patent estate after the acquisition. Teva also had a generic operating platform, creating potential portfolio-level control over both branded and generic commercialization.

The market structure created several competitive possibilities:

• Brand Nuvigil retained for higher-margin prescriptions.
• Teva-affiliated generic armodafinil used to capture price-sensitive demand.
• Third-party ANDA entrants applying pressure through automatic substitution.
• Multiple generic entrants driving rapid price erosion after the first commercial launch.

What was the revenue exposure?

Nuvigil was a meaningful Cephalon product before generic competition. Its revenue exposure arose from three sources:

1. Direct U.S. sales of branded Nuvigil.
2. Lost sales from generic substitution.
3. Reduced pricing power after the first generic launch.

The impact of generic entry would depend on the number of approved ANDAs, the availability of 180-day exclusivity, the timing of any settlement launch, payer substitution rules, and whether Teva marketed an authorized generic.

Nuvigil’s commercial risk was greater than a single-product patent-expiration analysis suggests. Once one generic entered, pharmacy substitution could rapidly shift volume away from the branded product. Later entrants would usually intensify price compression.

How did Nuvigil compare with Provigil?

Factor	Nuvigil	Provigil
Active ingredient	Armodafinil	Modafinil
Product type	R-enantiomer	Racemic modafinil
Brand company	Cephalon, later Teva	Cephalon, later Teva
Primary patent strategy	Later armodafinil composition and method patents	Earlier modafinil patents and settlements
FDA pathway for generics	ANDA	ANDA
Litigation risk	Formulation and method-of-use challenges	Composition, formulation, and use challenges
Generic exposure	Increased after Nuvigil patent litigation and settlements	Earlier generic competition

The Provigil and Nuvigil patent estates were related commercially but legally distinct. A favorable outcome in Provigil litigation would not automatically establish validity or infringement for Nuvigil patents.

What manufacturing and intellectual-property barriers remained?

The principal manufacturing barrier was not biologic complexity. Armodafinil is a chemically synthesized small molecule, and generic manufacturers could rely on the ANDA pathway rather than independently proving clinical efficacy.

Potential barriers included:

• Matching the reference-listed drug’s formulation.
• Demonstrating bioequivalence.
• Addressing formulation patents.
• Avoiding patented methods of use through label design.
• Establishing noninfringement positions for each listed patent.
• Managing Paragraph IV litigation costs.
• Securing FDA approval before the market became crowded.

These barriers could delay entry, but they were unlikely to support permanent market protection once the relevant patents expired or were settled.

Key Takeaways

• Cephalon Inc. v. Sandoz Inc., No. 1:14-cv-01239, was a Delaware Hatch-Waxman case involving generic armodafinil and Cephalon’s Nuvigil patent estate.
• The case ended without a reported merits decision on patent validity, infringement, or enforceability.
• Nuvigil’s initial FDA exclusivity had expired before the litigation, leaving later-issued patents as the principal barriers to generic entry.
• The relevant Nuvigil patent estate included formulation and method-of-use patents with expiration dates generally extending into the late 2020s.
• Sandoz’s challenge created the statutory approval-stay and Paragraph IV litigation framework typical of ANDA disputes.
• The public record does not establish a judicial finding that Sandoz infringed or that Cephalon’s asserted patents were invalid.
• Nuvigil faced substantial generic-entry risk after settlement or termination of the litigation because armodafinil is a small-molecule product eligible for ANDA approval.
• Teva’s acquisition of Cephalon gave it control over both the branded Nuvigil business and the associated patent portfolio.

FAQs About Cephalon v. Sandoz and Nuvigil Patent Litigation

What was the case number for Cephalon v. Sandoz?

The case was U.S. District Court for the District of Delaware Civil Action No. 1:14-cv-01239.

Was Nuvigil a biologic subject to biosimilar litigation?

No. Nuvigil contained armodafinil, a chemically synthesized small molecule. Generic competition proceeded through the ANDA pathway, not the biosimilar pathway.

Did the court invalidate the Nuvigil patents?

No reported merits decision in the case established invalidity of the asserted Nuvigil patents.

Did Sandoz receive permission to launch before the listed patents expired?

The public litigation record does not provide a reported judicial opinion establishing the specific settlement launch date or commercial launch terms.

What was the main commercial consequence of the case?

The case increased the probability of generic armodafinil entry and reduced the period during which Cephalon and later Teva could rely on Nuvigil’s branded market position.

References

1. Cephalon, Inc. v. Sandoz Inc., No. 1:14-cv-01239, U.S. District Court for the District of Delaware. (2014-2015). Court docket and pleadings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

4. U.S. Code, 21 U.S.C. § 355(j). Abbreviated applications for new drugs.

5. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System patent records for U.S. Patent Nos. 8,268,349, 8,338,457, 8,629,111, and 8,871,779. https://patentcenter.uspto.gov/